CSF biomarker levels in early and late onset Alzheimer's disease

OBJECTIVE To compare CSF levels of beta-amyloid 1-42 (Abeta(1-42)), total tau (tau) and tau phosphorylated at threonine 181 (ptau-181) between AD patients and controls according to age. METHODS 248 AD patients (48% men) and 127 controls (51% men, 22 volunteers and 105 subjective complainers) underwent lumbar puncture. Both patients and controls were divided into a young (<65 years) and old (>or=65 years) group. RESULTS All three biomarkers showed main effects of diagnosis (p<0.001). There was an interaction between diagnosis and age for all three biomarkers (p<0.05), as old controls had lower Abeta(1-42) and higher (p)tau than young controls (Abeta(1-42) 699+/-250 versus 866+/-191pg/ml, tau 408+/-245 versus 243+/-102pg/ml, ptau-181 60+/-28 versus 42+/-15pg/ml), but there was no difference according to age among AD patients (Abeta(1-42) 451+/-178 versus 425+/-146pg/ml, tau 741+/-460 versus 798+/-467pg/ml, ptau-181 91+/-42 versus 91+/-41pg/ml). CONCLUSION We found that the older control group had lower Abeta(1-42) and higher (p)tau compared to the younger control group. This suggests that older individuals may have AD pathology, even in the absence of objective cognitive impairment.

[1]  K. Blennow,et al.  CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study , 2003, Neurology.

[2]  E. Tangalos,et al.  CME Practice parameter: , 2022 .

[3]  M. Freedman,et al.  Frontotemporal lobar degeneration , 1998, Neurology.

[4]  S. Hirai,et al.  The levels of cerebrospinal fluid Aβ40 and Aβ42(43) are regulated age-dependently , 2001, Neurobiology of Aging.

[5]  Ge Li,et al.  Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. , 2006, Archives of neurology.

[6]  G. Frisoni,et al.  Structural correlates of early and late onset Alzheimer’s disease: voxel based morphometric study , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[7]  R. DeTeresa,et al.  Neocortical morphometry, lesion counts, and choline acetyltransferase levels in the age spectrum of Alzheimer's disease , 1988, Neurology.

[8]  K. Davis,et al.  Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease , 2006, Neurology.

[9]  D. A. Bennett,et al.  Memory complaints are related to Alzheimer disease pathology in older persons , 2006, Neurology.

[10]  Jan Six,et al.  Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme‐Linked Immunosorbent Assay , 1993 .

[11]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[12]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[13]  K. Blennow,et al.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.

[14]  Alistair Burns,et al.  Observations on the brains of demented old people. B.E. Tomlinson, G. Blessed and M. Roth, Journal of the Neurological Sciences (1970) 11, 205–242; (1968) 7, 331–356 , 1997 .

[15]  P. Scheltens,et al.  Amyloid β(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease , 2004, Neurology.

[16]  C. Bouras,et al.  Cerebrospinal fluid tau and Aβ42 concentrations in healthy subjects: delineation of reference intervals and their limitations , 2004, Clinical chemistry and laboratory medicine.

[17]  Hilkka Soininen,et al.  Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers , 2005, Annals of neurology.

[18]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[19]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[20]  K. Blennow,et al.  Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. , 2001, Clinical chemistry.

[21]  J. Jolles,et al.  Ten-year risk of dementia in subjects with mild cognitive impairment , 2006, Neurology.

[22]  K. Blennow,et al.  Cerebrospinal Fluid Beta-Amyloid 42 Is Reduced before the Onset of Sporadic Dementia: A Population-Based Study in 85-Year-Olds , 2003, Dementia and Geriatric Cognitive Disorders.

[23]  J. Morris,et al.  Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage alzheimer’s disease , 2001, Journal of Molecular Neuroscience.

[24]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[25]  Frederik Barkhof,et al.  CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease , 2008, Neurobiology of Aging.

[26]  K. Blennow,et al.  Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma , 2000, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[27]  H. Scrable,et al.  An aging pathway controls the TrkA to p75NTR receptor switch and amyloid β‐peptide generation , 2006, The EMBO journal.

[28]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[29]  I. Sokal,et al.  CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment , 2007, Neurology.

[30]  K. Jellinger,et al.  Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[31]  K. Blennow,et al.  CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging , 2000, Journal of Neural Transmission.

[32]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[33]  K. Blennow,et al.  Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization , 2000, Neuroscience Letters.

[34]  M. Rossor,et al.  Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease , 1999, Neuroscience Letters.

[35]  D. Schenk,et al.  Concentrations of amyloid-β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease , 1994, Neuroscience Letters.

[36]  Charles DeCarli,et al.  Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? , 2003, Archives of neurology.

[37]  E. Mandelkow,et al.  Tau in Alzheimer's disease. , 1998, Trends in cell biology.

[38]  G. K. Wilcock,et al.  Plaques, tangles and dementia A quantitative study , 1982, Journal of the Neurological Sciences.

[39]  M. Roth.  The natural history of mental disorder in old age. , 1955, The Journal of mental science.

[40]  W. M. van der Flier,et al.  Hippocampal atrophy in Alzheimer disease: Age matters , 2006, Neurology.

[41]  K. Blennow,et al.  Cerebrospinal fluid β-amyloid 1–42 concentration may predict cognitive decline in older women , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[42]  C. W. Tam,et al.  Subjective memory complaints in Chinese subjects with mild cognitive impairment and early Alzheimer's disease , 2005, International journal of geriatric psychiatry.

[43]  P. Scheltens,et al.  Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. , 1992, Journal of neurology, neurosurgery, and psychiatry.